|
1) Koike T, Ichikawa K, Kasahara H, et al. Epitopes on beta2-GPI recognized by anticardiolipin antibodies. Lupus. 1998; 7 (Suppl 2): S14-7
|
|
|
|
2) Schwarzenbacher R, Zeth K, Diederichs K, et al. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J. 1999; 18: 6228-39
|
|
|
|
|
|
3) Agar C, van Os GM, Morgelin M, et al. {beta}2-Glycoprotein I can exist in two conformations: implications for our understanding of the antiphospholipid syndrome. Blood (in press)
|
|
|
|
|
|
4) Yu P, Passam FH, Yu DM, et al. Beta2-glycoprotein I inhibits vascular endothelial growth factor and basic fibroblast growth factor induced angiogenesis through its amino terminal domain. J Thromb Haemost. 2008; 6: 1215-23
|
|
|
|
|
|
5) Nakagawa H, Yasuda S, Matsuura E, et al. Nicked {beta}2-glycoprotein I binds angiostatin 4. 5(plasminogen kringle 1-5)and attenuates its antiangiogenic property. Blood. 2009; 114: 2553-9
|
|
|
|
|
|
6) de Groot PG, Derksen RH, Urbanus RT. The role of LRP8 (ApoER2ʼ) in the pathophysiology of the antiphospholipid syndrome. Lupus. 2010; 19: 389-93
|
|
|
|
|
|
7) Bohgaki M, Matsumoto M, Atsumi T, et al. Plasma gelsolin facilitates interaction between beta (2) glycoprotein I and alpha 5 beta1 integrin. J Cell Mol Med (in press)
|
|
|
|
|
|
8) Sikara MP, Routsias JG, Samiotaki M, et al. {beta}2 Glycoprotein I({beta}2GPI)binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. Blood. 2010; 115: 713-23
|
|
|
|
|
|
9) Vlachoyiannopoulos PG, Routsias JG. A novel mechanism of thrombosis in antiphospholipid antibody syndrome. J Autoimmun. 2010 (in press)
|
|
|
|
|
|
10) Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol. 2005; 174: 485-90
|
|
|
|
|
|
11) Salmon JE, Girardi G, Lockshin MD. The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Nat Clin Pract Rheumatol. 2007; 3: 140-7
|
|
|
|
|
|
12) Thurman JM, Kraus DM, Girardi G, et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol. 2005; 42: 87-97
|
|
|
|
|
|
13) Sugiura-Ogasawara M, Nozawa K, Nakanishi T, et al. Complement as a predictor of further miscarriage in couples with recurrent miscarriages. Hum Reprod. 2006; 21: 2711-4
|
|
|
|
|
|
14) Pierangeli SS, Girardi G, Vega-Ostertag M, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum. 2005; 52: 2120-4
|
|
|
|
|
|
15) Oku K, Atsumi T, Bohgaki M, et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis. 2009; 68: 1030-5
|
|
|
|
|
|
16) Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009; 7: 1737-40
|
|
|
|
|